Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Otsuka Pharmaceutical Co. Ltd.

www.otsuka.co.jp/en/

Latest From Otsuka Pharmaceutical Co. Ltd.

Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications

The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.

Approvals Business Strategies

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals

Carogra, Xenpozyme Among Japan World-First Approvals

The latest batch of new drug approvals in Japan includes several products receiving their first marketing clearances globally, notably a new oral competitor to a blockbuster ulcerative colitis drug and a high-need therapy for the rare disease ASMD.

Japan Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
UsernamePublicRestriction

Register